Transforming Innovation into Biotherapeutics
FWB is building a portfolio of late stage pre-clinical and early clinical biotherapeutics through in-licensing and acquisition of novel 3rd party technology.
FWB’s first investment was in MGFB a company focused on exploiting a novel cancer vaccine platform licensed from the Mayo Clinic.
Medical innovations are precious, exciting and come from many different sources including small biotech, academia and individual entrepreneurs. Transforming a good idea into a biotherapeutic product is challenging and capital-intensive endeavor. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.
FairWinds Bio has assembled experts, advisors, service providers, and capital to deploy on late pre-clinical and early clinical assets to accelerate their development into products. The company has deep expertise in oncology but is open to other therapeutic areas as well.
Our extensive network seeks out exciting innovations, engages flexibly with the innovators, and accelerates the transition to biotherapeutics to address high unmet needs. If you think you have an innovation that fits our profile, please contact us.